MX337059B - Metodos y composiciones para modular la hemostasia. - Google Patents

Metodos y composiciones para modular la hemostasia.

Info

Publication number
MX337059B
MX337059B MX2012006837A MX2012006837A MX337059B MX 337059 B MX337059 B MX 337059B MX 2012006837 A MX2012006837 A MX 2012006837A MX 2012006837 A MX2012006837 A MX 2012006837A MX 337059 B MX337059 B MX 337059B
Authority
MX
Mexico
Prior art keywords
methods
hemostasia
modulate
compositions
variants
Prior art date
Application number
MX2012006837A
Other languages
English (en)
Inventor
Rodney M Camire
Original Assignee
Philadelphia Children Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philadelphia Children Hospital filed Critical Philadelphia Children Hospital
Publication of MX337059B publication Critical patent/MX337059B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a una variante del Factor Xa que modula la hemostasis que comprende al menos una mutación por substitución den los aminoácidos 41-179 y 235-488 de SEQ ID NO: 1, en donde la Val en la posición 236 se sustituye con un aminoácido en la posición 235 no es Val o Ala.
MX2012006837A 2005-11-15 2008-05-15 Metodos y composiciones para modular la hemostasia. MX337059B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73668005P 2005-11-15 2005-11-15

Publications (1)

Publication Number Publication Date
MX337059B true MX337059B (es) 2016-02-09

Family

ID=38049397

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2012006836A MX336958B (es) 2005-11-15 2006-03-21 Metodos y composiciones para modular la hemostasia.
MX2008006313A MX2008006313A (es) 2005-11-15 2006-03-21 Metodos y composiciones para modular la hemostasia.
MX2012006837A MX337059B (es) 2005-11-15 2008-05-15 Metodos y composiciones para modular la hemostasia.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2012006836A MX336958B (es) 2005-11-15 2006-03-21 Metodos y composiciones para modular la hemostasia.
MX2008006313A MX2008006313A (es) 2005-11-15 2006-03-21 Metodos y composiciones para modular la hemostasia.

Country Status (25)

Country Link
US (4) US8383386B2 (es)
EP (4) EP1948690B1 (es)
JP (4) JP5823088B2 (es)
KR (4) KR101574042B1 (es)
CN (1) CN101356192B (es)
AU (1) AU2006315175B2 (es)
BR (1) BRPI0618654B1 (es)
CA (2) CA2971971A1 (es)
CR (1) CR9956A (es)
DK (1) DK1948690T3 (es)
EC (1) ECSP088452A (es)
ES (2) ES2496567T3 (es)
GT (1) GT200800065A (es)
IL (1) IL191310A (es)
MX (3) MX336958B (es)
MY (1) MY162181A (es)
NO (3) NO345177B1 (es)
NZ (1) NZ568108A (es)
PL (1) PL1948690T3 (es)
PT (1) PT1948690E (es)
RU (2) RU2008123398A (es)
SI (1) SI1948690T1 (es)
SV (1) SV2008002906A (es)
WO (1) WO2007059513A2 (es)
ZA (1) ZA200804026B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2193196T (pt) 2007-09-28 2016-10-24 Portola Pharm Inc Antídotos para inibidores do fator xa e métodos de utilização dos mesmos
CN102316893B (zh) 2008-11-14 2015-02-18 博尔托拉制药公司 因子Xa抑制剂的解毒剂及其与血液凝固剂组合使用的方法
DK3604510T3 (da) 2009-03-30 2025-06-30 Alexion Pharma Inc Antidoter til faktor-Xa-hæmmere og fremgangsmåder til anvendelse deraf
CN102625712B (zh) 2009-07-15 2017-07-25 博尔托拉制药公司 用于因子xa抑制剂的解毒剂的单位剂量制剂及其使用方法
CA2812888A1 (en) 2010-10-06 2012-04-12 Medimmune Limited Factor ii and fibrinogen for treatment of haemostatic disorders
JP6514893B2 (ja) * 2011-09-30 2019-05-15 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ 止血を調節するための組成物および方法
CN104755492A (zh) * 2012-07-25 2015-07-01 催化剂生物科学公司 修饰的因子x多肽及其应用
AU2014210830A1 (en) * 2013-01-31 2015-07-16 Pfizer Inc. Compositions and methods for counteracting Factor Xa inhibition
FR3001729B1 (fr) * 2013-02-04 2015-03-06 Lab Francais Du Fractionnement Mutants du facteur x
CN105579468A (zh) * 2013-09-24 2016-05-11 辉瑞大药厂 包含重组人凝血因子Xa蛋白的异质性群体的组合物
WO2015066606A2 (en) * 2013-11-01 2015-05-07 The Children's Hospital Of Philadelphia Compositions and methods for increasing the half-life of factor xa
PT3096779T (pt) * 2014-01-24 2020-02-21 Pfizer Composições e métodos para tratamento de hemorragia intracerebral
ES2813440T3 (es) * 2014-05-26 2021-03-23 Academisch Ziekenhuis Leiden Proteínas prohemostáticas para el tratamiento del sangrado
US10676731B2 (en) 2014-08-19 2020-06-09 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor IX function
CA3034566A1 (en) 2016-07-27 2018-02-01 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor ix function
US20250066436A1 (en) 2021-12-22 2025-02-27 Royal College Of Surgeons In Ireland A conjugate for use in localising a molecule to the vascular endothelium

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093699A (en) 1987-07-09 2000-07-25 The University Of Manitoba Method for gene therapy involving suppression of an immune response
WO1994017810A1 (en) 1993-02-12 1994-08-18 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
CA2160583A1 (en) 1993-04-16 1994-10-27 Stanley A. Plotkin Recombinant cytomegalovirus vaccine
AU7676894A (en) 1993-08-27 1995-03-21 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Convection-enhanced drug delivery
AT401270B (de) 1994-09-26 1996-07-25 Immuno Ag Verfahren zur quantifizierung von genomischer dna
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6100242A (en) 1995-02-28 2000-08-08 The Regents Of The University Of California Gene therapies for enhancing cardiac function
WO1997032481A1 (en) 1996-03-07 1997-09-12 The Regents Of The University Of California Helper-free, totally defective adenovirus for gene therapy
AT405517B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
AT405516B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
AT410216B (de) 1999-08-10 2003-03-25 Baxter Ag Faktor x-analogon mit verbesserter aktivierbarkeit
US20040102388A1 (en) * 2000-03-22 2004-05-27 High Katherine A. Modified blood clotting factors and methods of use
FR2831170B1 (fr) * 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
FR2841904B1 (fr) * 2002-07-03 2004-08-20 Inst Nat Sante Rech Med Analogues de facteurs x clivables par la thrombine
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
US8436144B2 (en) * 2008-12-19 2013-05-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Serine protease derivatives and uses in the prevention or the treatment of blood coagulation disorders

Also Published As

Publication number Publication date
JP6236194B2 (ja) 2017-11-22
IL191310A (en) 2015-06-30
US9896676B2 (en) 2018-02-20
CR9956A (es) 2008-08-21
KR20080078664A (ko) 2008-08-27
RU2008123398A (ru) 2009-12-27
JP5823088B2 (ja) 2015-11-25
NO20200671A1 (no) 2008-07-30
BRPI0618654B1 (pt) 2021-10-19
WO2007059513A2 (en) 2007-05-24
US20180251745A1 (en) 2018-09-06
NO20200670A1 (no) 2008-07-30
SI1948690T1 (sl) 2014-09-30
NO345177B1 (no) 2020-10-26
US9410137B2 (en) 2016-08-09
KR101827569B1 (ko) 2018-02-09
EP1948690B1 (en) 2014-06-11
MX2008006313A (es) 2008-11-06
CN101356192A (zh) 2009-01-28
GT200800065A (es) 2008-11-03
US20160362673A1 (en) 2016-12-15
NO20082182L (no) 2008-07-30
ES2549929T3 (es) 2015-11-03
PT1948690E (pt) 2014-09-08
NZ568108A (en) 2011-09-30
US20140120155A1 (en) 2014-05-01
EP1948690A4 (en) 2009-06-17
PL1948690T3 (pl) 2014-11-28
RU2570547C2 (ru) 2015-12-10
DK1948690T3 (da) 2014-09-01
BRPI0618654A2 (pt) 2011-09-06
CA2629491C (en) 2019-05-07
CA2971971A1 (en) 2007-05-24
EP2423224B1 (en) 2015-08-12
KR20140005383A (ko) 2014-01-14
JP2016005464A (ja) 2016-01-14
MX336958B (es) 2016-02-05
HK1165444A1 (en) 2012-10-05
EP2431390A1 (en) 2012-03-21
KR20160029135A (ko) 2016-03-14
JP2009515559A (ja) 2009-04-16
KR20140115374A (ko) 2014-09-30
ZA200804026B (en) 2009-10-28
JP2018033459A (ja) 2018-03-08
SV2008002906A (es) 2008-10-22
EP2431389A1 (en) 2012-03-21
KR101600158B1 (ko) 2016-03-08
JP6571735B2 (ja) 2019-09-04
HK1128699A1 (en) 2009-11-06
WO2007059513A3 (en) 2007-11-29
ECSP088452A (es) 2008-07-30
MY162181A (en) 2017-05-31
CN101356192B (zh) 2013-09-11
RU2011130932A (ru) 2013-01-27
EP1948690A2 (en) 2008-07-30
ES2496567T3 (es) 2014-09-19
KR101574042B1 (ko) 2015-12-03
JP5957167B2 (ja) 2016-07-27
EP2423224A1 (en) 2012-02-29
AU2006315175A1 (en) 2007-05-24
BRPI0618654A8 (pt) 2019-01-15
CA2629491A1 (en) 2007-05-24
AU2006315175B2 (en) 2013-02-07
EP2431390B1 (en) 2015-08-12
US8383386B2 (en) 2013-02-26
US20090175931A1 (en) 2009-07-09
JP2014073127A (ja) 2014-04-24

Similar Documents

Publication Publication Date Title
MX337059B (es) Metodos y composiciones para modular la hemostasia.
CR10213A (es) Moduladores de la proteína quinasa aurora
CY1113102T1 (el) Ενωσεις φαινυλπροπιοναμιδιου και η χρηση αυτων
CU20070160A7 (es) Pirrolopirazoles, inhibidores potentes de quinasa
NO20092637L (no) Fremgangsmater for behandling
NO20071127L (no) Triazoloftalaziner
DE602008000754D1 (de) Tropanverbindungen
CR11373A (es) COMPUESTOS DE TIENOPIRIMIDINA Y PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE mTOR CINASA Y PI3 CINASA
EA200802008A1 (ru) Фармацевтические композиции
SV2009003434A (es) Inhibicion de arni de expresion de alfa-enac
EA201100037A1 (ru) Органические соединения
CY2014011I2 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
CL2008000873A1 (es) Compuestos derivados de pirrolidin amidas; composicion farmaceutica que comprende dichos compuestos; y su uso para tratar trombosis.
CR10094A (es) Carbonilamino pirrolopirazoles, potentes inhibidores de quinasa
PL2215071T3 (pl) Proleki tetrahydrokannabinolu, kompozycje zawierające proleki tetrahydrokannabinolu i sposoby ich stosowania
EP2068864A4 (en) THERAPEUTIC USES OF UROLITHINES
UY29853A1 (es) Derivados de diacilindazol como inhibidores de lipasas y fosfolipasas-
BRPI0813000A2 (pt) Composições terapêuticas e uso das mesmas
UY31484A1 (es) Piperidinas heteroaril-sustituidas
PL2214656T3 (pl) Kompozycje i sposoby wzmacniania odpowiedzi immunologicznej
BRPI0720211A2 (pt) Derivado de indanona, composição, e, uso de uma composição
DK1988877T3 (da) Terapeutiske sammensætninger omfattende ingenol-3-angelat
EA200870515A1 (ru) Моноциклические гетероарильные соединения
EP1951050A4 (en) THERAPEUTIC COMPOSITIONS AND METHOD
UY30801A1 (es) Compuestos calciliticos